跳至主要内容
临床试验/CTIS2023-506512-40-00
CTIS2023-506512-40-00进行中(未招募)1 期

Effect of low-dose arginine-vasopressin supplementation on post-transplant Acute Kidney Injury after liver transplantation - AVENIR Trial - APHP220827

Assistance Publique Hopitaux De Paris0 个研究点目标入组 304 人开始时间: 2023年10月2日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
304

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • Age = 18 years, Any adult patient with a scheduled liver transplantation, All participants will need to be given clear information about the study and give signed informed consent, Person affiliated to the Social Security

排除标准

  • Super-emergency for liver transplantation or fulminant hepatitis, Pregnancy or breastfeeding, Patient listed for or receiving simultaneous liver-kidney transplantation (SLKT), Patients with end-stage renal disease (chronic eGFR < 15 mL/min/1.73 m2 or requiring extra-renal purification before liver transplantation, Patient with epilepsy, Hypersensitivity to arginine-vasopressin and to its excipients, Patient refusal, Patients for whom it is impossible to give informed consent (language barrier), Adults under guardianship or trusteeship, persons deprived of their liberty, Patient enrolled in another interventional clinical study

研究者

相似试验